Bioxcel Therapeutics Stock Performance
| BTAI Stock | USD 1.91 0.03 1.55% |
On a scale of 0 to 100, BioXcel Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 1.52, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioXcel Therapeutics will likely underperform. Please check BioXcel Therapeutics' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether BioXcel Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioXcel Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating basic indicators, BioXcel Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 65.2 M |
BioXcel Therapeutics Relative Risk vs. Return Landscape
If you would invest 171.00 in BioXcel Therapeutics on April 20, 2025 and sell it today you would earn a total of 20.00 from holding BioXcel Therapeutics or generate 11.7% return on investment over 90 days. BioXcel Therapeutics is currently generating 0.3632% in daily expected returns and assumes 6.2143% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than BioXcel, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioXcel Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioXcel Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioXcel Therapeutics, and traders can use it to determine the average amount a BioXcel Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0584
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BTAI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.21 actual daily | 55 55% of assets are less volatile |
Expected Return
| 0.36 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average BioXcel Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioXcel Therapeutics by adding it to a well-diversified portfolio.
BioXcel Therapeutics Fundamentals Growth
BioXcel Stock prices reflect investors' perceptions of the future prospects and financial health of BioXcel Therapeutics, and BioXcel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioXcel Stock performance.
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (60.11) % | ||||
| Current Valuation | 86.61 M | ||||
| Shares Outstanding | 6.06 M | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 6.34 X | ||||
| Revenue | 2.27 M | ||||
| EBITDA | (44.16 M) | ||||
| Cash And Equivalents | 233.45 M | ||||
| Cash Per Share | 8.33 X | ||||
| Total Debt | 102.95 M | ||||
| Debt To Equity | 0.38 % | ||||
| Book Value Per Share | (16.49) X | ||||
| Cash Flow From Operations | (72.03 M) | ||||
| Earnings Per Share | (11.12) X | ||||
| Total Asset | 38.34 M | ||||
| Retained Earnings | (650.2 M) | ||||
| Current Asset | 609.37 K | ||||
| Current Liabilities | 1.67 M | ||||
About BioXcel Therapeutics Performance
By evaluating BioXcel Therapeutics' fundamental ratios, stakeholders can gain valuable insights into BioXcel Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioXcel Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioXcel Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. Bioxcel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Things to note about BioXcel Therapeutics performance evaluation
Checking the ongoing alerts about BioXcel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioXcel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioXcel Therapeutics had very high historical volatility over the last 90 days | |
| BioXcel Therapeutics may become a speculative penny stock | |
| BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.27 M. Net Loss for the year was (59.6 M) with loss before overhead, payroll, taxes, and interest of (225 K). | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (72.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing BioXcel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioXcel Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining BioXcel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioXcel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioXcel Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioXcel Therapeutics' stock. These opinions can provide insight into BioXcel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |